RxDoctor Payments Data

Jenny Shaffer, MD

Radiation Oncology · St Louis, MONPI 1073838322

Payments from drug & device makers

$633in general payments, 2019–2025

Across 24 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$239
  • Novocure Inc.$98
  • Novartis$68
  • Boston Scientific$60
  • GT Medical Technologies, Inc$39
  • Bayer$39
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$633 in reported general payments places this provider in the 40th percentile of 123 radiation oncology providers in Missouri.

See all radiation oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$209,650
Medicare patients
253
Services billed
2,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix84$219,549
MyrbetriqMirabegron14$10,645
Cevimeline Hcl31$3,472
Megestrol Acetate26$1,739
Tamsulosin Hcl53$1,084
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$1,014
Dexamethasone52$794
Gabapentin34$769
Bicalutamide11$748
Oxycodone Hcl17$680
Lidocaine Hcl ViscousLidocaine Hcl42$641
Sucralfate31$534
Memantine Hcl24$441
Pilocarpine Hcl11$433
Nystatin27$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$28$219,54984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 123 radiation oncology providers in Missouri.

Other radiation oncology in St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →